NCT07515391Enrolling by invitationPhase 2
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 11 Dec 2019
- Start date
- 22 Oct 2019
- Primary completion date
- 1 May 2021
- Lead sponsor
- Dasman Diabetes Institute
- Diseases
- Type 2 diabetes
- NCT number
- NCT07515391
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 22 Oct 2019 to the primary completion date, 1 May 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients using insulin therapy or a sulfonylurea.
Other illness
- Type 1 diabetes
- Secondary diabetes
- History of ketoacidosis
- History of pancreatitis and pancreatectomy.
- Uncontrolled hypertension.
- Uncontrolled thyroid disease.
- Any history of serious hypertension reaction to the dapagliflozin or SGLT-2 inhibitor.
- History of malignancy within 5-year of screening.
- Presence of any other medical condition that would in the opinion of the investigator, preclude safe participation in the study.
Lab values
- History of primary renal glycosuria or hereditary glucose-galactose malabsorption.
- Active diabetes complications, nephropathy (dipstick positive proteinuria, or reduced eGFR (\<60 ml/min), proliferative retinopathy.
- HbA1c \>10.5
Other
- Clinically significant abnormal liver function test.
- Pregnant ladies, or intending pregnancy or breastfeeding.
- Unable to sign the consent form.
Who the study is looking for
- People diagnosed with type 2 diabetes prior to bariatric surgery.
- People did not have diabetes prior to bariatric surgery.
- Willing to participate in this study.
Age in the registry: 21 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dasman Diabetes Institute Coordinator of this site? Confirm its status | Kuwait City | Kuwait | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.